CTI Clinical Trial and Consulting Services, the international drug and device development organisation based in Cincinnati, US, has set up a wholly owned subsidiary in Italy and opened an office in Milan.

The office came on the back of the newly created subsidiary, CTI Clinical Trial and Consulting Services Italy, S.R.L..

The market for clinical research continues to grow throughout Europe, and Italy is “a key location,” explained CTI general manager Patrick Earley.

“Milan has a very dynamic economy, serving as a hub for the Italian pharmaceutical and biotechnology industries, which makes it ideal for a new location,” Earley added.

“We have had ongoing relationships with many key Italian research leaders for several years, and this expansion will allow us to continue to enhance our collaborations.”

Seventh in Europe

The Milan office is CTI’s seventh in Europe and the second European office it has opened this year.

In May the company announced the formation of a Polish subsidiary, CTI Clinical Trial and Consulting Services Poland, sp. z o.o., and opened an office in Warsaw.

Last year saw CTI establish a UK affiliate and set up an office outside London in July. That followed its expansion into France with a wholly owned subsidiary and a Paris office in May 2012.

CTI has been active for nearly fifteen years in drug development across North America, Europe and South America, specialising in clinical research programmes involving critically ill patient populations